Published in Blood on July 15, 1995
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother (1998) 1.27
Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis (1997) 1.04
Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging (2005) 1.00
G-CSF and GM-CSF in Neutropenia. J Immunol (2015) 0.98
Clinical uses of GM-CSF, a critical appraisal and update. Biologics (2008) 0.97
Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine. Mil Med Res (2015) 0.94
Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans. Antimicrob Agents Chemother (2001) 0.88
Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res Hum Retroviruses (2008) 0.87
The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS One (2014) 0.87
Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis. Infect Immun (1997) 0.86
Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood (2004) 0.83
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res (2013) 0.83
Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med (2012) 0.79
Invasive mold infections in solid organ transplant recipients. Scientifica (Cairo) (2014) 0.79
Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr (2003) 0.79
Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study. Clin Med Insights Oncol (2010) 0.78
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol (2016) 0.77
Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol (2012) 0.76
Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial. BMC Cancer (2002) 0.75
The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia. PLoS One (2017) 0.75
[Myelopoiesis and bone marrow function in elderly tumor patients]. Z Gerontol Geriatr (2012) 0.75
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 13.98
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
Changes in physicians' attitudes toward telling the cancer patient. JAMA (1979) 7.75
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 6.82
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer (1981) 5.89
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. Ann Intern Med (1973) 3.81
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 3.16
Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med (1984) 3.07
Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med (1982) 2.97
Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med (1972) 2.75
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 2.68
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood (2000) 2.65
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia (2003) 2.53
Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med (1977) 2.52
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol (1989) 2.36
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1995) 2.33
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 2.22
Cytogenetic features of human neuroblastomas and cell lines. Cancer Res (1981) 2.21
PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood (2001) 2.20
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med (1984) 2.09
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus (2001) 2.04
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol (1989) 2.02
Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol (1989) 1.85
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
Characterization and significance of abnormal leukocyte granules in the beige mouse: a possible homologue for Chediak-Higashi Aleutian trait. J Lab Clin Med (1969) 1.80
Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol (1995) 1.80
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med (1974) 1.77
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Phase I clinical and pharmacokinetic study of taxol. Cancer Res (1987) 1.74
Social exchange and well-being: is giving better than receiving? Psychol Aging (2001) 1.73
Ineffectiveness of AL721 in HIV disease. Lancet (1990) 1.73
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol (1995) 1.70
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol (1991) 1.66
The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol (1981) 1.64
Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer (1990) 1.59
Antigen detection in the diagnosis of invasive aspergillosis. Utility in controlled, blinded trials. Ann Intern Med (1983) 1.59
Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol (1993) 1.55
Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med (1975) 1.53
Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med (1981) 1.53
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol (1991) 1.52
Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1994) 1.51
Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect Dis (1974) 1.51
Defective granulocyte regulation in the Chediak-Higashi syndrome. N Engl J Med (1968) 1.51
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Prolonged venous access for chemotherapy by means of the Hickman catheter. Cancer (1983) 1.49
Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer (1994) 1.46
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res (2000) 1.45
Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol (1991) 1.44
Factors affecting survival in nocardiosis. Am Rev Respir Dis (1973) 1.44
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol (1987) 1.44
Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant (2003) 1.43
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol (2002) 1.42
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood (2000) 1.41
Anticipation in familial plasma cell dyscrasias. Br J Haematol (1998) 1.41
Electrophoretic distribution of serum proteins of normal and an arthritic white-tailed deer (Odocoileus virginianus). Am J Vet Res (1969) 1.41
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol (1999) 1.40
Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med (1980) 1.40
Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004. Transfus Med (2007) 1.40
Rectal abscesses in cancer patients. Lancet (1972) 1.40
Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma (2000) 1.39
Danazol treatment of myelodysplastic syndromes. Br J Haematol (1991) 1.39
Meta-analyses need new publication standards. J Clin Oncol (1992) 1.39
Acute promyelocytic leukemia: another pseudoleukemia? Blood (1990) 1.38